Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Coley Pharmaceutical Group Broadens Leading Toll-like Receptor (TLR) Platform Through Strategic Acquisition of 3M Company's TLR Therapeutic Research and Development Programs
June 27th, 2007
Coley Pharmaceutical Group, Inc. (NASDAQ:COLY) announced that it has entered into an agreement with 3M Company (NYSE:MMM) to acquire the majority of their therapeutic Toll-like receptor (TLR) cancer programs. The acquisition includes a pipeline of clinical and preclinical small molecule candidates targeting TLR7 and TLR8, as well an extensive intellectual property estate of more than 200 issued and several hundred pending patents and an extensive library of approximately 10,000 small molecule compounds that stimulate TLR7 and TLR8. Coley anticipates initiating Phase I/II clinical trials in a cancer indication in 2008 with one of the newly-acquired TLR small molecules. ...
Source: Medical Patent Law Weekly (2007-06-27)
|
|
Advertisement |
|
|
|
